Nuclear karyopherin a2: A novel biomarker for infiltrative astrocytomas

Journal of Neuro-Oncology

Volumn 109, Issue 3, 2012, Pages 545-553

  Gousias, K ^a   Becker, A J ^a   Simon, M ^a   Niehusmann, P ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Biomarker; IDH1 mutation; Infiltrative astrocytomas; Karyopherin a2; NBS1 protein; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ISOCITRATE DEHYDROGENASE 1; KARYOPHERIN; KARYOPHERIN A2; KI 67 ANTIGEN; NIBRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CELL NUCLEUS; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR RECURRENCE;

ADULT; ALPHA KARYOPHERINS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866043312     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0924-2     Document Type: Article

References (33)

1. Central brain tumor registry of the United States. http://www.cbtrus.org/ 2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. Accessed 20 January 2012
2. Stummer W, Reulen HJ, Meinel T, Pichlmeier W, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T ALA-Glioma Study Group (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62(3):564-576
3. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vanden Berg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. JCO 26:1338-1345
4. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479 (Pubitemid 28482012)
5. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13(23):6933-6937 (Pubitemid 350276872)
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003 (Pubitemid 40349502)
7. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27(8):1257-1261
8. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707-718
9. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M, German Glioma Network (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17(13):4588-4599
10. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719-729
11. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452-460
12. Yan H, Parsons DW, Jin G, McLendon R, Rasheed A, Yuan W, Kos I, Batinic-Haberle I, Jones I, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler WK, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
13. Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, Delia D (2003) Karyophrin-a2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem 278:42346-42351 (Pubitemid 37310504)
14. Tseng SF, Chang CY, Wu KJ, Teng SC (2005) Importin KPNA2 is required for proper nuclear localization and multiple functions of NSB1. J Biol Chem 280:39594-39600
15. Chen YC, Su YN, Chou PC, Chiang WC, Chang MC, Wang LS, Teng SC, Wu KJ (2005) Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt. J Biol Chem 280(37):32505-32511
16. Teng SC, Wu KJ, Tseng SF, Wong CW, Kao L (2006) Importin KPNA2, NSB1, DNA repair and tumorigenesis. J Mol Histol 37:293-299 (Pubitemid 44795632)
17. Antoccia A, Kobayashi J, Tauchi H, Matsuura S, Komatsu K (2006) Nijmegen breakage syndrome and functions of the responsible protein, NSB1. Genome Dyn 1:191-205
18. Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP, Choi SY, Song BJ, Kim ER, Bae YS, Moon YH (2000) Truncated form of importin a identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 275:23139-23145
19. Moll UM, LaQuaqlia M, Benard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407-4411
20. Noetzel E, Rose M, Bornemann J, Gajewski M, Knüchel R, Dahl E (2011) Nuclear transport receptor karyopherin-a2 promotes malignant breast cancer phenotypes in vitro. Oncogene doi. doi: 10.1038/onc.2011.403 21.
21. http://www.ebi.ac.uk/gxa/gene/ENSG00000182481?ef=disease-state#efv= glioblastoma. Accessed 12 March 2012 22.
22. http://www.genecards.org/cgi-bin/carddisp. pl?gene=KPNA2. Accessed 12 March 2012
23. Zheng M, Tang L, Huang L, Ding H, Liao WT, Zeng MS, Wang H (2010) Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 116(4):884-891
24. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ (2006) Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin a2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 12(13):3950-3960 (Pubitemid 44078080)
25. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD (2009) The karyopherin proteins, Crm1 and Karyopherin b1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829-1840
26. Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstädter F, Hartmann A, Jaggi R, Moch H, Kristiansen G, Wild PJ (2011) KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 17(5):1111-1121
27. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98(7):472-482
28. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutationspecific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245-254
29. Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, Hartmann A, Kristiansen G (2007) KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch 451:877-881 (Pubitemid 350060752)
30. Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nilz UA, Hartmann A (2008) Nuclear karyopherin a2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 123:1433-1438
31. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histological grade to improve prognosis. J Natl Cancer Inst 98:262-272 (Pubitemid 43264710)
32. Wang CI, Wang CL, Wang CW, Chen CD, Wu CC, Liang Y, Tsai YH, Chang YS, Yu JS, Yu CJ (2010) Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer 128(10):2364-2372
33. Mirzoeva OK, Kawaguchi T, Pieper RO (2006) The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol Cancer Ther 5(11):2757-2766 (Pubitemid 44849002)